| Line 594: | Line 594: | ||
==Tourette Syndrome== | ==Tourette Syndrome== | ||
===2012 [https://pubmed.ncbi.nlm.nih.gov/22776623/ Translating laboratory discovery to the clinic: from nicotine and mecamylamine to Tourette's, depression, and beyond]=== | |||
* The article presents a mini-review of studies on TS and depression over the past 25 years. | |||
* It summarizes the studies on the behavioral biology of the basal ganglia and its neurotransmitters. | |||
* It describes research with TS patients to evaluate the therapeutics of nicotine and mecamylamine. | |||
* [https://sci-hub.se/10.1016/j.physbeh.2012.06.023 PDF Version] | |||
*Citation: Sanberg, P. R., Vindrola-Padros, C., & Shytle, R. D. (2012). Translating laboratory discovery to the clinic: From nicotine and mecamylamine to Tourette’s, depression, and beyond. Physiology & Behavior, 107(5), 801–808. doi:10.1016/j.physbeh.2012.06.023 | |||
*Acknowledgement: Paul R. Sanberg and R. Douglas Shytle are inventors on patents related to technology described herein and licensed from the University of South Florida to Targacept, Inc. Because of the historical nature of this article, the authors included a number of self-citations required for a chronological discussion. | |||
===2004 [https://pubmed.ncbi.nlm.nih.gov/15132126/ Clinical and attentional effects of acute nicotine treatment in Tourette's syndrome]=== | |||
*In the 14 evaluable patients with complete primary efficacy data, nicotine (compared to placebo) failed to alter symptoms at 4 hours, but counteracted [https://en.wikipedia.org/wiki/P300_(neuroscience) ERP-P300] signs of diminished attention seen 2 weeks following placebo treatment. | |||
*Secondary efficacy measures, including patient self-reports and parental ratings, found nicotine to reduce complex tics and improve behaviors related to inattention. | |||
*[https://sci-hub.st/10.1016/j.eurpsy.2003.11.002 PDF Version ] | |||
*Citation: Howson, A. L., Batth, S., Ilivitsky, V., Boisjoli, A., Jaworski, M., Mahoney, C., & Knott, V. J. (2004). Clinical and attentional effects of acute nicotine treatment in Tourette’s syndrome. European Psychiatry, 19(2), 102–112. doi:10.1016/j.eurpsy.2003.11.002 | |||
*Acknowledgement: This study was supported with a grant from the Tourette Syndrome Association (USA), and patient recruitment was aided by the Ottawa chapter of the Tourette Syndrome Foundation of Canada. | |||
===2001 [https://pubmed.ncbi.nlm.nih.gov/11681767/ Transdermal nicotine and haloperidol in Tourette's disorder: a double-blind placebo-controlled study]=== | ===2001 [https://pubmed.ncbi.nlm.nih.gov/11681767/ Transdermal nicotine and haloperidol in Tourette's disorder: a double-blind placebo-controlled study]=== | ||
| Line 599: | Line 617: | ||
*[https://www.researchgate.net/profile/Paul_Sanberg/publication/11670769_Transdermal_Nicotine_and_Haloperidol_in_Tourette's_Disorder/links/5be32624299bf1124fc2d86a/Transdermal-Nicotine-and-Haloperidol-in-Tourettes-Disorder.pdf PDF Version] | *[https://www.researchgate.net/profile/Paul_Sanberg/publication/11670769_Transdermal_Nicotine_and_Haloperidol_in_Tourette's_Disorder/links/5be32624299bf1124fc2d86a/Transdermal-Nicotine-and-Haloperidol-in-Tourettes-Disorder.pdf PDF Version] | ||
*Citation: Silver AA, Shytle RD, Philipp MK, Wilkinson BJ, McConville B, Sanberg PR. Transdermal nicotine and haloperidol in Tourette's disorder: a double-blind placebo-controlled study. J Clin Psychiatry. 2001 Sep;62(9):707-14. doi: 10.4088/jcp.v62n0908. PMID: 11681767. | *Citation: Silver AA, Shytle RD, Philipp MK, Wilkinson BJ, McConville B, Sanberg PR. Transdermal nicotine and haloperidol in Tourette's disorder: a double-blind placebo-controlled study. J Clin Psychiatry. 2001 Sep;62(9):707-14. doi: 10.4088/jcp.v62n0908. PMID: 11681767. | ||
===1997 [https://www.sciencedirect.com/science/article/abs/pii/S0163725896001994 Nicotine for the treatment of Tourette's syndrome]=== | ===1997 [https://www.sciencedirect.com/science/article/abs/pii/S0163725896001994 Nicotine for the treatment of Tourette's syndrome]=== | ||
| Line 607: | Line 626: | ||
* Acknowledgements-This review was supported, in part, by grants from the Tourette Syndrome Association, The National Institute of Neurological Disease and Stroke (ROl NS 32067sOlAl) and the Smokeless Tobacco Research Council. | * Acknowledgements-This review was supported, in part, by grants from the Tourette Syndrome Association, The National Institute of Neurological Disease and Stroke (ROl NS 32067sOlAl) and the Smokeless Tobacco Research Council. | ||
*Keywords: Nicotine; Tourette's syndrome; tics; neuropsychiatric disorders | *Keywords: Nicotine; Tourette's syndrome; tics; neuropsychiatric disorders | ||
===1996 [https://pubmed.ncbi.nlm.nih.gov/9006184/ Does nicotine have beneficial effects in the treatment of certain diseases?]=== | ===1996 [https://pubmed.ncbi.nlm.nih.gov/9006184/ Does nicotine have beneficial effects in the treatment of certain diseases?]=== | ||
| Line 613: | Line 633: | ||
*[https://sci-hub.st/10.12968/bjon.1996.5.19.1195 PDF Version] | *[https://sci-hub.st/10.12968/bjon.1996.5.19.1195 PDF Version] | ||
*Citation: Birtwistle J, Hall K. Does nicotine have beneficial effects in the treatment of certain diseases? Br J Nurs. 1996 Oct 24-Nov 13;5(19):1195-202. doi: 10.12968/bjon.1996.5.19.1195. PMID: 9006184. | *Citation: Birtwistle J, Hall K. Does nicotine have beneficial effects in the treatment of certain diseases? Br J Nurs. 1996 Oct 24-Nov 13;5(19):1195-202. doi: 10.12968/bjon.1996.5.19.1195. PMID: 9006184. | ||
=== 1996 [https://pubmed.ncbi.nlm.nih.gov/8973070/ Case study: long-term potentiation of neuroleptics with transdermal nicotine in Tourette's syndrome]=== | === 1996 [https://pubmed.ncbi.nlm.nih.gov/8973070/ Case study: long-term potentiation of neuroleptics with transdermal nicotine in Tourette's syndrome]=== | ||
| Line 619: | Line 640: | ||
*[https://sci-hub.st/10.1097/00004583-199612000-00015 PDF Version] | *[https://sci-hub.st/10.1097/00004583-199612000-00015 PDF Version] | ||
*Citation: Silver AA, Shytle RD, Philipp MK, Sanberg PR. Case study: long-term potentiation of neuroleptics with transdermal nicotine in Tourette's syndrome. J Am Acad Child Adolesc Psychiatry. 1996 Dec;35(12):1631-6. doi: 10.1097/00004583-199612000-00015. PMID: 8973070. | *Citation: Silver AA, Shytle RD, Philipp MK, Sanberg PR. Case study: long-term potentiation of neuroleptics with transdermal nicotine in Tourette's syndrome. J Am Acad Child Adolesc Psychiatry. 1996 Dec;35(12):1631-6. doi: 10.1097/00004583-199612000-00015. PMID: 8973070. | ||
===1992 [https://pubmed.ncbi.nlm.nih.gov/1643197/ The effects of nicotine plus haloperidol compared to nicotine only and placebo nicotine only in reducing tic severity and frequency in Tourette's disorder]=== | ===1992 [https://pubmed.ncbi.nlm.nih.gov/1643197/ The effects of nicotine plus haloperidol compared to nicotine only and placebo nicotine only in reducing tic severity and frequency in Tourette's disorder]=== | ||
| Line 625: | Line 647: | ||
* Citation: McConville BJ, Sanberg PR, Fogelson MH, King J, Cirino P, Parker KW, Norman AB. The effects of nicotine plus haloperidol compared to nicotine only and placebo nicotine only in reducing tic severity and frequency in Tourette's disorder. Biol Psychiatry. 1992 Apr 15;31(8):832-40. doi: 10.1016/0006-3223(92)90315-q. PMID: 1643197. | * Citation: McConville BJ, Sanberg PR, Fogelson MH, King J, Cirino P, Parker KW, Norman AB. The effects of nicotine plus haloperidol compared to nicotine only and placebo nicotine only in reducing tic severity and frequency in Tourette's disorder. Biol Psychiatry. 1992 Apr 15;31(8):832-40. doi: 10.1016/0006-3223(92)90315-q. PMID: 1643197. | ||
*Acknowledgements: Supported in part by grants from the Smokeless Tobacco Research Council, Inc., the Tourette Syndrome Association, and Merrell Dow Pharmaceuticals. The authors thank Roger Stuebing, B.S.M.E., M.S.I.E., and Sunny Y. Lu, M.D., Ph.D. for statistical advice and Merrell Dow Pharmaceuticals for supplying both Nicoreue® gum and placebo nicotine gum. | *Acknowledgements: Supported in part by grants from the Smokeless Tobacco Research Council, Inc., the Tourette Syndrome Association, and Merrell Dow Pharmaceuticals. The authors thank Roger Stuebing, B.S.M.E., M.S.I.E., and Sunny Y. Lu, M.D., Ph.D. for statistical advice and Merrell Dow Pharmaceuticals for supplying both Nicoreue® gum and placebo nicotine gum. | ||
===1991 [https://pubmed.ncbi.nlm.nih.gov/1859921/ Beneficial effects of nicotine]=== | ===1991 [https://pubmed.ncbi.nlm.nih.gov/1859921/ Beneficial effects of nicotine]=== | ||
| Line 631: | Line 654: | ||
*Citation: Jarvik ME. Beneficial effects of nicotine. Br J Addict. 1991 May;86(5):571-5. doi: 10.1111/j.1360-0443.1991.tb01810.x. PMID: 1859921. | *Citation: Jarvik ME. Beneficial effects of nicotine. Br J Addict. 1991 May;86(5):571-5. doi: 10.1111/j.1360-0443.1991.tb01810.x. PMID: 1859921. | ||
*Acknowledgement: Supported by U. C. Tobacco-related Disease program, grant # RT87 and a grant from the John D. and Catherine T. MacArthur Foundation. | *Acknowledgement: Supported by U. C. Tobacco-related Disease program, grant # RT87 and a grant from the John D. and Catherine T. MacArthur Foundation. | ||
===1989 [https://www.sciencedirect.com/science/article/abs/pii/002432058990444X?via%3Dihub Nicotine and cannabinoids as adjuncts to neuroleptics in the treatment of tourette syndrome and other motor disorders]=== | ===1989 [https://www.sciencedirect.com/science/article/abs/pii/002432058990444X?via%3Dihub Nicotine and cannabinoids as adjuncts to neuroleptics in the treatment of tourette syndrome and other motor disorders]=== | ||
| Line 637: | Line 661: | ||
*Citation: D.E. Moss, Patricia Z. Manderscheid, S.P. Montgomery, Andrew B. Norman, Paul R. Sanberg, Nicotine and cannabinoids as adjuncts to neuroleptics in the treatment of tourette syndrome and other motor disorders, Life Sciences, Volume 44, Issue 21, 1989, Pages 1521-1525, ISSN 0024-3205, doi.org/10.1016/0024-3205(89)90444-X. | *Citation: D.E. Moss, Patricia Z. Manderscheid, S.P. Montgomery, Andrew B. Norman, Paul R. Sanberg, Nicotine and cannabinoids as adjuncts to neuroleptics in the treatment of tourette syndrome and other motor disorders, Life Sciences, Volume 44, Issue 21, 1989, Pages 1521-1525, ISSN 0024-3205, doi.org/10.1016/0024-3205(89)90444-X. | ||
*Acknowledgements: Supported in part by NIMH (RR 08012) and NIDA. Levonantradol and fluphenazine HCL were generous gifts from Pfizer Pharmaceuticals (Groton, Conn.) and E.R. Squibb and Sons (Princeton, N.J.), respectively. | *Acknowledgements: Supported in part by NIMH (RR 08012) and NIDA. Levonantradol and fluphenazine HCL were generous gifts from Pfizer Pharmaceuticals (Groton, Conn.) and E.R. Squibb and Sons (Princeton, N.J.), respectively. | ||
==Weight Loss / Appetite Control / Metabolism / Obesity== | ==Weight Loss / Appetite Control / Metabolism / Obesity== | ||
edits